 GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc NASDAQ: RARE have received clearance from Health Canada to begin enrolling in the Phase 12 study of GTX-102 pediatric patients with Angelman syndrome in Canada. Angelman syndrome is a rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. 